DepoMed Inc. (DEPO)
-NasdaqGS 5.79 
0.08(1.40%) May 23, 4:00PM EDT
| Prev Close: | 5.71 |
|---|
| Open: | 5.71 |
|---|
| Bid: | 5.20 x 800 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 8.13 |
|---|
| Beta: | 1.16 |
|---|
| Next Earnings Date: | 2-Aug-13 |
|---|
| Day's Range: | 5.65 - 5.82 |
|---|
| 52wk Range: | 4.91 - 7.15 |
|---|
| Volume: | 404,760 |
|---|
| Avg Vol (3m): | 567,795 |
|---|
| Market Cap: | 327.15M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.47 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- DEPOMED INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Mon, May 20)
- DEPOMED INC FinancialsEDGAR Online Financials(Fri, May 17)
- Socially Responsible Investing in Biotech and Pharmaceutical Companies: Expert Portfolio Manager Finny Kuruvilla Discusses His Construction Strategy with The Wall Street TranscriptWall Street Transcript(Thu, May 16)
- Depomed To Present At UBS Global Healthcare ConferencePR Newswire(Thu, May 16)
- Special Dividend and Ongoing Cash Distributionat Motley Fool(Tue, May 14)
- DepoMed CEO Buys 25K Shares and 4 Insider Trades to Noteat Wall St. Cheat Sheet(Tue, May 14)
- Monday 5/13 Insider Buying Report: DEPO, LNBBat Forbes(Mon, May 13)
- Did These Stocks Miss or Beat Analyst Expectations?at Wall St. Cheat Sheet(Sun, May 12)
- The Gory Details on DepoMed's Double Missat Motley Fool(Thu, May 9)
- Review Of Depomed First Quarter 2013 Resultsat Seeking Alpha(Thu, May 9)
- DEPOMED INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- DepoMed Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- DepoMed Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Wed, May 8)
- Depomed Earnings Call scheduled for 4:30 pm ET todayCCBN(Wed, May 8)
- Depomed Reports First Quarter 2013 Financial ResultsPR Newswire(Wed, May 8)
Key Statistics
| Forward P/E (1 yr): | 14.85 |
|---|
| P/S (ttm): | 3.22 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.10 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.05 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | -1.83 |
|---|
Business Summary
Depomed, Inc., a specialty pharmaceutical company, focuses on developing products for pain and other conditions, and diseases of the central nervous system in the United States.
View More